Table 1 Characteristics of abstracted studies
Author, year | Region | Patients with AML | Control | Sample type | Assay method | Study type | Criteria for the classification of AML | NOS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | Age, mean ± sd, years | % female | VEGF mean ± sd, pg/ml | N | Age, mean ± sd, years | % female | VEGF, mean ± sd, pg/ml | |||||||
Aguayo et al., 2000 [16] | American | 115 | NA | NA | 30.43 ± 69.63 | 11 | NA | NA | 32.63 ± 9.50 | Plasma | ELISA | Case-control | NA | 6 |
Aguayo et al., 2002 [27] | American | 58 | NA | NA | 30.63 ± 92.09 | 43 | 39.00 ± 13.75 | NA | 27.30 ± 17.08 | Plasma | ELISA | Case-control | FAB | 7 |
Aref et al., 2002 [25] | Egypt | 63 | 47.00 ± 12.50 | 28/63 | 78.00 ± 47.25a | 15 | NA | NA | 33.03 ± 13.76a | Plasma | ELISA | Case-control | FAB | 7 |
Wang et al., 2003 [28] | China | 39 | 42.00 ± 14.75 | 19/39 | 135.30 ± 87.90 | 12 | NA | NA | 80.60 ± 33.10 | Plasma | ELISA | Case-control | NA | 6 |
Xie and Qi, 2003 [24] | China | 25 | NA | NA | 201.43 ± 51.84 | 30 | 36.71 ± 11.75 | 14/30 | 100.53 ± 47.67 | Serum | ELISA | Case-control | FAB | 6 |
Wierzbowska et al., 2003 [30] | Poland | 38 | NA | NA | 32.60 ± 651.20 | 12 | NA | NA | 44.40 ± 31.60 | Plasma | ELISA | Case-control | FAB | 6 |
Wang et al., 2004 [29] | China | 107 | 42.00 ± 11.83 | 59/107 | 154.75 ± 109.98 | 26 | NA | NA | 99.91 ± 41.87 | Plasma | ELISA | Case-control | FAB | 6 |
Kim et al., 2005 [17] | Korea | 28 | 41.50 ± 14.75b | NA | 54.30 ± 113.15 | 17 | NA | NA | 238.95 ± 136.25 | Serum | ELISA | Case-control | NA | 6 |
Aref et al., 2005 [26] | Egypt | 43 | NA | NA | 373.90 ± 222.95 | 10 | NA | NA | 138.00 ± 14.86 | Plasma | ELISA | Case-control | FAB | 6 |
Erdem et al., 2006 [23] | Turkey | 15 | 32.60 ± 18.80 | 5/15 | 110.10 ± 120.90 | 20 | 34.00 ± 11.90 | 8/20 | 69.90 ± 24.40 | Serum | ELISA | Case-control | NA | 7 |
Zhao and Zhao, 2007 [22] | China | 15 | NA | NA | 377.49 ± 146.31 | 15 | NA | NA | 77.11 ± 21.37 | Serum | ELISA | Case-control | NA | 6 |
Dincaslan et al., 2010 [31] | Turkey | 7 | 7.17 ± 4.84 | 4/7 | 286.50 ± 328.81 | 20 | NA | NA | 190.50 ± 117.50 | Serum | ELISA | Case-control | FAB | 7 |
Song et al., 2015 [21] | China | 28 | NA | NA | 74.97 ± 29.04 | 10 | NA | NA | 41.76 ± 10.03 | Serum | ELISA | Case-control | FAB/WHO | 7 |
Yang et al., 2016 [20] | China | 68 | 51.00 ± 12.37 | 32/68 | 293.21 ± 57.54 | 20 | 49.00 ± 8.94 | 10/20 | 133.00 ± 24.65 | Plasma | ELISA | Case-control | FAB/WHO | 7 |